Abbvie-Header Abbvie-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IBI302

            Therapeutic Area: Ophthalmology Product Name: IBI302

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 30, 2021


            IBI302 has ability to inhibit the proliferation of VEGF-mediated signaling pathway and reduce the inflammatory response mediated by complement activation. The primary objective of the study is to evaluate the efficacy and safety of IBI302 in the treatment of nAMD.